Frontiers in Psychology
September 14, 2022
Yuchao Li, Jinghui Chen, Baoxia Chen et al.
PurposeThis study systematically evaluates the effect of mindfulness meditation on depression during pregnancy. We provide evidence-based suggestions for preventing and reducing depression during pregnancy by exploring the most effective intervention mode, cycle, and frequency of mindfulness meditation.MethodsRecords were retrieved from PubMed, Web of Science, EBSCO, and Science Direct. A total...
Ketamine Revisited - New Insights into NMDA Inhibitors
September 14, 2022
Tahani K. Alshammari, Sarah Alseraye, Nouf M. Alrasheed et al.
Our knowledge regarding pathological and treatment resistance mechanisms involved in depression is far from understood. Sexual dimorphism in this topic is well acknowledged. However, the need to highlight sex-based discrepancies is unmet. Ketamine, the dissociative anesthetic, has emerged as a rapid antidepressant. This chapter reviewed sexual dimorphism in pharmacological and genetic models of...
The Journal of Clinical Psychiatry
September 12, 2022
P. Oliver, A. Snyder, R. Feinn et al.
Introduction: Few studies have been published to date exploring the effectiveness of ketamine for treatment-resistant depression (TRD) in large clinical samples. We report on the clinical outcomes of a large cohort treated with ketamine as part of clinical practice. Methods: Deidentified electronic chart data were obtained from a multisite private ketamine infusion clinic for 424 patients with...
Journal of Technology in Behavioral Science
September 10, 2022
Jeyaseelan Maria Michael, Marc Eric S Reyes
The outbreak of the Covid-19 pandemic has led to the intensive use of the internet for educational and recreational purposes, leading adolescents to be more exposed to cyberbullying. Empirical studies indicate that cyberbullying has become a pervasive problem among adolescents causing negative consequences like depression. Moreover, the global pandemic lockdown and quarantine measures gave rise...
September 8, 2022
Adam Safron, Matthew Johnson
5 citations
preprint
Here we consider psychedelics with respect to their mechanisms of action, use, and implications for our understandings of brain and mind. This review is somewhat nontraditional in its scope, with discussions of both basic facts as well as theoretical speculations. We chose this approach given the unique historical context we find ourselves in at present. While we have decades of investigations...
Molecular Psychiatry
September 7, 2022
Rebecca B Price, Nicholas Kissel, Andrew Baumeister et al.
80 citations
Abstract Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset antidepressant properties, but little is known regarding which patients are most likely to benefit, limiting personalized prescriptions. We identified randomized controlled trials of IV ketamine that recruited individuals with a relevant psychiatric diagnosis (e.g., unipolar or bipolar...
Læknablaðið
September 6, 2022
Arny Johannesdottir, Engilbert Sigurðsson
4 citations
The hallucinogen psilocybin is a potential novel treatment for treatment-resistant depression (TRD). Our goal is to review current knowledge on psilocybin and its efficacy in TRD. Literature searches were done on PubMed, Web of Science and Google Scholar, references reviewed in identified articles and other articles found on the website of COMPASS Pathways. Psilocybin treatment consists usually...
Mindfulness
September 2022
Matthew J. Hirshberg, Blake A Colaianne, Mark Greenberg et al.
Significant concerns have been raised about the "mental health crisis" on college campuses, with attention turning to what colleges can do beyond counseling services to address students' mental health and well-being. We examined whether primarily first-year (89.1%) undergraduate students (n=651) who enrolled in the Art and Science of Human Flourishing (ASHF), a novel academic and experiential...
BMJ Open
September 1, 2022
Katarina Tabi, Manreet Bhullar, Lenssa Fantu et al.
Introduction: Postpartum depression and anxiety (PPDA) is experienced by up to 20% of families in the first year. The condition impacts not only parents but also their developing child. While mindfulness-based interventions (MBI) have shown to be beneficial for this population, many parents do not have access to treatment or find it challenging to commit or complete the treatment. The COVID-19...
Epilepsy & Behavior
September 2022
Tina Makris, Diana S Dorstyn
Research on third-wave cognitive behavioral therapies has burgeoned over the last ten years. However, questions remain about the effectiveness of these therapies for people with epilepsy. This article provides an up-to-date review of the current evidence-base. Following protocol registration (PROSPERO CRD42021269882), two reviewers searched six databases (from inception until 1 March 2022) for...
Journal of clinical psychology in medical settings
September 2022
Oskar Lundgren, Peter Garvin, Lennart Nilsson et al.
Depressive symptoms after coronary events are associated with a worse prognosis. When changing the focus from psychopathology towards a resilience framework, treatments such as mindfulness meditation could offer novel ways to address psychological distress among coronary artery disease (CAD) patients. We studied the feasibility of mindfulness-based stress reduction (MBSR) for CAD patients with...
Journal of Affective Disorders
September 1, 2022
Melody J Y Kang, Gustavo Vazquez
BACKGROUND Major Depression is the leading cause of disability worldwide. A cohort of patients do not respond adequately to available antidepressants, leading to treatment-resistant depression (TRD). We evaluated the antidepressant efficacy of an acute intravenous ketamine treatment (0.5 mg/kg) for patients with unipolar TRD, and measured peripheral blood-based biomarkers associated with...
Journal of Affective Disorders
September 1, 2022
Madeline Brendle, Reid Robison, D. Malone
OBJECTIVE The aim of this study was to estimate the cost-effectiveness of esketamine nasal spray relative to intravenous ketamine for patients with treatment-resistant depression (TRD) in the US. METHODS We used a Markov model with a 1-month cycle length, and we estimated quality-adjusted life years (QALYs), costs (2020 USD), and incremental cost-effectiveness ratios (ICER) of esketamine...
International Clinical Psychopharmacology
September 1, 2022
Joseph C.W. Tham, André Do, Jason Fridfinnson et al.
Interest in the use of parenteral ketamine has been increasing over the last 2 decades for the management of treatment-resistant depression (TRD). While intravenous (IV) ketamine has been the most common parenteral route of administration, subcutaneous (SC) and intramuscular options have been described. We developed a clinical treatment protocol for the use of repeated SC racemic ketamine...
BMJ Open
September 1, 2022
Gustavo Vazquez, Gilmar Gutierrez, Joshua D. Rosenblat et al.
6 citations
INTRODUCTION: Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits. The objective of this observational study is to elucidate the association of intranasal (IN) esketamine with beneficial and negative outcomes in the management of...
Psychiatry and Clinical Psychopharmacology
September 1, 2022
Mihriban Heval Özgen, W. van den Brink
In this case report, we present an adult male patient with autism spectrum disorder and a comorbid (treatment-resistant) mood disorder with suicidality. He has been treated with numerous psychopharmaceuticals, most recently risperidone and valproic acid. He has been hospitalized several times and has attempted suicide. He displayed limited social functioning, repetitive behaviors, sensory...
Journal of Affective Disorders
September 1, 2022
Bing Zhang, Wenxian Fu, Yan Guo et al.
BACKGROUND Mindfulness-based cognitive therapy (MBCT) can effectively prevent relapse of major depression, but there is currently insufficient evidence for efficacy against suicidal ideation during depressive episodes. We thus conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing MBCT to treatment as usual (TAU) for suppression of suicidal ideation in...
Nature and Science of Sleep
September 1, 2022
Tian‐He Song, Tingting Wang, Yun‐Yue Zhuang et al.
13 citations
Purpose: Nightmare is common and is also independently implicated in suicide risk among the adolescent population. Adolescents with major depressive disorder (MDD) are at an increased risk of suicide. Therefore, comorbid nightmares may amplify suicide risk among this clinical population. This study aimed to explore the effects of nightmares on suicide risk among adolescents with MDD. Patients...
The Brown University Psychopharmacology Update
September 1, 2022
A medication combining dextromethorphan and bupropion was more efficacious than an active comparator and placebo in reducing depressive symptoms in adults with major depressive disorder, a pair of trials has found. Remission rates with dextromethorphan‐bupropion separated from the comparator and placebo by week 2 of treatment in each study, according to researchers. Results of the Phase 2 trial...
Psychiatric Annals
September 1, 2022
Fernando Espí Forcén, Maren Nyer
To date, ketamine is the only prescribable psychedelic medicine in the United States. Ketamine is also one of the most promising drugs for the treatment of depression. In the current paradigm of care, most ketamine clinics in the United States treat patients with mood disorders with ketamine and its derivatives alone without psychotherapy. The purpose of this article is to review the most...